Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with
immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We …
immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We …
[HTML][HTML] Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events …
E Verzoni, G Cartenì, E Cortesi, D Giannarelli… - … for immunotherapy of …, 2019 - Springer
Abstract Background The Italian Renal Cell Cancer Early Access Program was an expanded
access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell …
access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell …
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 …
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC)
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …
Influenza vaccine indication during therapy with immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
M Bersanelli, D Giannarelli, P Castrignanò… - …, 2018 - Future Medicine
Aim: Considering the unmet need for the counseling of cancer patients treated with immune
checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to …
checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to …
BRAF mutant NSCLC and immune checkpoint inhibitors: results from a real-world experience
K Rihawi, D Giannarelli, D Galetta, A Delmonte… - Journal of Thoracic …, 2019 - jto.org
1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in
metastatic nonsmall-cell lung cancer. N Engl J Med. 2018; 378: 2078–2092. 2. Liu D, Zhao …
metastatic nonsmall-cell lung cancer. N Engl J Med. 2018; 378: 2078–2092. 2. Liu D, Zhao …
[HTML][HTML] The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 …
Background Nephrectomy is considered the backbone of managing patients with localized
and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy …
and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy …
New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
M Ghidini, JC Hahne, F Trevisani, S Panni… - … and clinical risk …, 2016 - Taylor & Francis
Neutropenia and febrile neutropenia are two major complications of chemotherapy. Dose
reductions, delays in treatment administration, and the use of granulocyte colony-stimulating …
reductions, delays in treatment administration, and the use of granulocyte colony-stimulating …
[HTML][HTML] The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal …
Background: Treatment choice for metastatic renal cell carcinoma (mRCC) patients is still
based on baseline clinical and laboratory factors. Methods: By a pre-specified analysis of …
based on baseline clinical and laboratory factors. Methods: By a pre-specified analysis of …
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study
Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of
influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) …
influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) …